Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trialReinhard Dummer, Keith T. Flaherty, Dirk Schadendorf et al.|The Lancet Oncology|2017Cited by 491
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trialJohn M. Kirkwood, Georgina V. Long, Michele Del Vecchio et al.|Nature Medicine|2023Cited by 208
T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both <i>In Vitro</i> and <i>In Vivo</i>Claudia Geldres, Gianpietro Dotti, Barbara Savoldo et al.|Clinical Cancer Research|2013Cited by 100
Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlusVictoria Atkinson, Michele Del Vecchio, Caroline Robert et al.|European Journal of Cancer|2022Cited by 30
Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in <i>NRAS</i>-mutant cutaneous melanoma.Reinhard Dummer, Keith T. Flaherty, Dirk Schadendorf et al.|Journal of Clinical Oncology|2016Cited by 30